Pharmacologic Treatment of Osteogenesis Imperfecta: New Agents and their Potential Implications for Osteogenesis Imperfecta - Osteogenesis Imperfecta - page 480

[50] Sutherland MK, Geoghegan JC, Yu C, Turcott E, Skonier JE,
Winkler DG, et al. Sclerostin promotes the apoptosis of human
osteoblastic cells: a novel regulation of bone formation. Bone
2004;35(4):828-35.
[51] Poole KE, van Bezooijen RL, Loveridge N, Hamersma H,
Papapoulos SE, Lowik CW, et al. Sclerostin is a delayed secreted
product of osteocytes that inhibits bone formation. FASEB J
2005;19(13):1842-4.
[52] Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M,
et al. Increased bone density in sclerosteosis is due to the dei-
ciency of a novel secreted protein (SOST). Hum Mol Genet 2001;
10(5):537-43.
[53] Lewiecki EM. Sclerostin: a novel target for intervention in the
treatment of osteoporosis. Discov Med 2011;12(65):263-73.
[54] Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, et al. Sclerostin
binds to LRP5/6 and antagonizes canonical wnt signaling. J Biol
Chem 2005;280(20):19883-7.
[55] Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D'Agostin D,
et al. Targeted deletion of the sclerostin gene in mice results in
increased bone formation and bone strength. J Bone Miner Res
2008;23(6):860-9.
[56] Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J,
et al. Sclerostin antibody treatment increases bone formation,
bone mass, and bone strength in a rat model of postmenopausal
osteoporosis. J Bone Miner Res 2009;24(4):578-88.
[57] UCB commence CDP7851/AMG 785 phase 3 trial in postmeno-
pausal osteoporosis. [Internet]: Amgen; 2012 [cited April 28, 2012].
Available from: < http://www.news-medical.net/news/20120404/
Amgen-UCB-commence-CDP7851AMG-785-Phase-3-trial-in-
postmenopausal-osteoporosis.aspx > .
[58] Padhi D, Jang G, Stouch B, Fang L, Posvar E. Single-dose, pla-
cebo-controlled, randomized study of AMG 785, a sclerostin
monoclonal antibody. J Bone Miner Res 2011;26(1):19-26.
[59] UCB and amgen initiate sclerostin antibody phase 3 program in
patients with postmenopausal osteoporosis [Internet]: Amgen;
2012 [updated April 4, 2012; cited April 30, 2012]. Available from:
< http://www.biotechnology-europe.com/news/news%20
by%20company/Amgen/2012/04.04.2012%20UCB%20and%20
Amgen%20Initiate%20Sclerostin%20Antibody%20Phase%203%20
Program%20in%20Patients%20With%20Postmenopausal%20Oste-
oporosis.html > .

[66] Tsourdi E, Rachner TD, Rauner M, Hamann C, Hofbauer LC.

Denosumab for bone diseases: translating bone biology into tar-
geted therapy. Eur J Endocrinol 2011;165(6):833-40.

[67] Lewiecki EM, Miller PD, McClung MR, Cohen SB, Bolognese

MA, Liu Y, et al. Two-year treatment with denosumab (AMG
162) in a randomized phase 2 study of postmenopausal women
with low BMD. J Bone Miner Res 2007;22(12):1832-41.

[68] Delos D, Yang X, Ricciardi BF, Myers ER, Bostrom MP, Camacho

NP. The effects of RANKL inhibition on fracture healing and
bone strength in a mouse model of osteogenesis imperfecta.
J Orthop Res 2008;26(2):153-64.

[69] Bargman R, Huang A, Boskey AL, Raggio C, Pleshko N. RANKL

inhibition improves bone properties in a mouse model of osteo-
genesis imperfecta. Connect Tissue Res 2010;51(2):123-31.

[70] Bargman R, Posham R, Boskey AL, DiCarlo E, Raggio C,

Pleshko N. Comparable outcomes in fracture reduction and
bone properties with RANKL inhibition and alendronate treat-
ment in a mouse model of osteogenesis imperfecta. Osteoporos
Int 2012;23(3):1141-50.

[71] Bromme D, Lecaille F. Cathepsin K inhibitors for osteoporo-

sis and potential off-target effects. Expert Opin Investig Drugs
2009;18(5):585-600.

[72] Xia L, Kilb J, Wex H, Li Z, Lipyansky A, Breuil V, et al.

Localization of rat cathepsin K in osteoclasts and resorption pits:
inhibition of bone resorption and cathepsin K-activity by pepti-
dyl vinyl sulfones. Biol Chem 1999;380(6):679-87.

[73] Fujisaki K, Tanabe N, Suzuki N, Kawato T, Takeichi O,

Tsuzukibashi O, et al. Receptor activator of NF-kappaB ligand
induces the expression of carbonic anhydrase II, cathepsin K, and
matrix metalloproteinase-9 in osteoclast precursor RAW264.7 cells.
Life Sci 2007;80(14):1311-8.

[74] Schilling AF, Mulhausen C, Lehmann W, Santer R, Schinke T,

Rueger JM, et al. High bone mineral density in pycnodysostotic
patients with a novel mutation in the propeptide of cathepsin K.
Osteoporos Int 2007;18(5):659-69.

[75] Pennypacker BL, Duong le T, Cusick TE, Masarachia PJ, Gentile

MA, Gauthier JY, et al. Cathepsin K inhibitors prevent bone loss
in estrogen-deicient rabbits. J Bone Miner Res 2011;26(2):252-62.

[76] Cusick T, Chen CM, Pennypacker BL, Pickarski M, Kimmel D,

Scott BB, et al. Odanacatib treatment increases hip bone mass
and cortical thickness by preserving endocortical bone forma-
tion and stimulating periosteal bone formation in the ovariecto-
mized adult rhesus monkey. J Bone Miner Res 2012;27(3):524-37.

[60] Gallacher SJ, Dixon T. Impact of treatments for postmenopausal

osteoporosis (bisphosphonates, parathyroid hormone, strontium
ranelate, and denosumab) on bone quality: a systematic review.
Calcif Tissue Int 2010;87(6):469-84.

[77] Eisman JA, Bone HG, Hosking DJ, McClung MR, Reid IR,

Rizzoli R, et al. Odanacatib in the treatment of postmenopausal
women with low bone mineral density: three-year continued ther-
apy and resolution of effect. J Bone Miner Res 2011;26(2):242-51.

[61] Reginster JY, Deroisy R, Jupsin I. Strontium ranelate: a new

paradigm in the treatment of osteoporosis. Drugs Today (Barc)
2003;39(2):89-101. [78] Stoch SA, Zajic S, Stone J, Miller DL, Van Dyck K, Gutierrez

MJ, et al. Effect of the cathepsin K inhibitor odanacatib on bone
resorption biomarkers in healthy postmenopausal women: Two
double-blind, randomized, placebo-controlled phase I studies.
Clin Pharmacol Ther 2009;86(2):175-82.

[62] Reginster JY, Sarlet N, Lejeune E, Leonori L. Strontium ranelate:

a new treatment for postmenopausal osteoporosis with a dual
mode of action. Curr Osteoporos Rep 2005;3(1):30-4.

[63] O'Donnell S, Cranney A, Wells GA, Adachi JD, Reginster JY.

Strontium ranelate for preventing and treating postmenopausal
osteoporosis. Cochrane Database Syst Rev 2006;3(3) CD005326.

[79] Jayakar RY, Cabal A, Szumiloski J, Sardesai S, Phillips EA, Laib A,

et al. Evaluation of high-resolution peripheral quantitative computed
tomography, inite element analysis and biomechanical testing in a
pre-clinical model of osteoporosis: a study with odanacatib treatment
in the ovariectomized adult rhesus monkey. Bone 2012;50(6):1379-88.

[64] Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid

IR, et al. Denosumab for prevention of fractures in postmenopausal
women with osteoporosis. N Engl J Med 2009;361(8):756-65.

[65] McClung MR, Lewiecki EM, Cohen SB, Bolognese MA,

Woodson GC, Moffett AH, et al. Denosumab in postmeno-
pausal women with low bone mineral density. N Engl J Med
2006;354(8):821-31.

[80] Bone HG, McClung MR, Roux C, Recker RR, Eisman JA,

Verbruggen N, et al. Odanacatib, a cathepsin-K inhibitor for osteo-
porosis: a two-year study in postmenopausal women with low
bone density. J Bone Miner Res 2010;25(5):937-47.